We are thrilled to welcome Jessica to the RAPT leadership team at this pivotal time for the company,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “With her deep expertise as both an ...

Apellis’s injectable C3 inhibitor Empaveli (pegcetacoplan) is also in phase 2 for C3G, and approved for PNH, while Omeros Corp is running early-stage clinical trials of a MASP-3-targeting ...

Aspaveli – which is known as Empaveli in the US – performed significantly better than Soliris, with patients taking it seeing an average increase of 2.4 g/dL in haemoglobin levels, while those ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a ...

1 Day APLS -4.22% DJIA -0.60% S&P Mid Cap 400 -0.18% Health Care/Life Sciences 0.16% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

At close: 5:29:42 PM GMT+2 ...

Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...